Meeting
2013 ASCO Annual Meeting
Prospective comparison of uPA/PAI-1 and endopredict-clin score in ER-positive, HER2-negative breast cancer: Impact on risk stratification and treatment decisions.
Authors
Johannes Ettl
Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
Johannes Ettl , Kirsten Grosse Lackmann , Alexander Hapfelmeier , Evelyn Klein , Stefan Paepke , Christoph Petry , Katja Specht , Heinz Hoefler , Marion Kiechle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 31, 2013 (suppl; abstr 581)
DOI
10.1200/jco.2013.31.15_suppl.581
Abstract #
581
Poster Bd #
6D
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET).
First Author: Adam Brufsky
Poster
2023 ASCO Annual Meeting
Risk stratification tools to help decide on adjuvant chemotherapy usage in resected soft tissue sarcomas: A 10 year review of an Irish sarcoma centre experience.
First Author: Catherine Weadick
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2017 ASCO Annual Meeting
Clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions incorporated the 21-gene recurrence score (RS): Elderly (≥70 yrs) vs younger patients (Pts).
First Author: Salomon M. Stemmer